

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

MAP4 RABBIT PAB

货号: S216825 产品全名: MAP4 兔多抗 基因符号

UNIPROT ID: P27816 (Gene Accession - BC008715)


背景: The protein encoded by this gene is a major non-neuronal microtubule-associated protein. This protein contains a domain similar to the microtubule-binding domains of neuronal microtubule-associated protein (MAP2) and microtubule-associated protein tau (MAPT/TAU). This protein promotes microtubule assembly, and has been shown to counteract destabilization of interphase microtubule catastrophe promotion. Cyclin B was found to interact with this protein, which targets cell division cycle 2 (CDC2) kinase to microtubules. The phosphorylation of this protein affects microtubule properties and cell cycle progression. Multiple transcript variants encoding different isoforms have been found for this gene.

抗原: Fusion protein of human MAP4 经过测试的应用: ELISA, IHC 推荐稀释比: IHC: 15-50; ELISA: 1000-2000 种属反应性: Rabbit 克隆性: Rabbit Polyclonal 亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human 成分: PBS (without Mg2+ and Ca2+), pH 7.4


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Cancer

储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human ovarian cancer tissue using 216825(MAP4 Antibody) at a dilution of 1/10(Cytoplasm).



The image on the left is immunohistochemistry of paraffinembedded Human thyroid cancer tissue using 216825(Anti-MAP4 Antiback) at a dilution at 140

In comparision with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with the fusion protein and then with 216825(Anti-MAP4 Antibody) at dilution 1/10.



In comparision with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with fusion protein and



Product Description

Pioneering GTPase and Oncogene Product Development since 2010